查看2017.HSA.doxorubicin.AC.vs.ADTIC的源代码
←
2017.HSA.doxorubicin.AC.vs.ADTIC
跳转到:
导航
,
搜索
因为以下原因,你没有权限编辑本页:
您刚才请求的操作只有这个用户组中的用户才能使用:
用户
您可以查看并复制此页面的源代码:
==='''统计分析 (Statistical analysis)'''=== 从诊断之日到最后一次就诊或死亡之日的随访和生存时间是根据在作者所在机构进行的复查计算的。对于两组,使用 Kaplan-Meier 乘积限值方法探索生存时间和 TTM(超出区域淋巴结),然后进行对数秩检验。在两组中,手术切除的时机都被认为是。在生存分析中,如果狗在数据累积关闭时还活着或死于没有肿瘤相关原因,则对狗进行审查,而对于TTM狗,如果在最后一次检查中没有发生远处转移,则被审查。 Follow-up and survival times were calculated from the date of diagnosis to the date of last visit or death based on the rechecks performed at one of the authors’ institutions. For both groups, survival time and TTM (beyond regional lymph nodes) were explored using the Kaplan–Meier product limit method followed by log-rank test. In either group, timing was considered from surgical excision. In the survival analysis, dogs were censored if they were alive at the time of data accrual closure or died of no tumour-related causes, whereas for TTM dogs were censored if, by the last examination, distant metastases had not developed. 为了验证两个治疗组的特征在入院时是否不同,使用 Mann-Whitney 检验比较年龄和体重,并使用 Fisher 精确检验比较品种(纯种与杂交)、性别(雄性与雌性)、肿瘤的主要位置(脾脏与其他部位)、临床分期(II 与 III)和手术切缘(完全与不完全)。如果狗出现内脏破裂,则认为手术切缘不可评估。Fisher 精确测试还用于比较治疗周期中发生的骨髓毒性(存在与不存在)的频率。P <0.05 被认为是显著的。 To verify whether characteristics of the two treatment groups differed at admission, the Mann–Whitney test was used to compare age and body weight, and the Fisher’s exact test was used to compare breed (pure- versus cross-breed), sex (male versus female), primary location of the tumour (spleen versus other sites), clinical stage (II versus III) and surgical margins (complete versus incomplete). Surgical margins were deemed not assessable if the dog was presenting with visceral rupture. The Fisher’s exact test was also used to compare the frequency of bone marrow toxicity (present versus absent) that occurred during treatment cycles. P <0.05 was considered significant.
返回到
2017.HSA.doxorubicin.AC.vs.ADTIC
。
个人工具
登录
名字空间
页面
讨论
变换
查看
阅读
查看源代码
查看历史
操作
搜索
导航
首页
社区专页
新闻动态
最近更改
随机页面
帮助
工具箱
链入页面
相关更改
特殊页面